Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5fadc18369dac6778fe6217aed49ada7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4826 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4833 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4853 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6432 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21006 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 |
filingDate |
2008-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abf6c738d0ea1b72717dbace5593c3be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efb2211f16469f38c373c4d4aca72098 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e652cb1cf998325aa0d2c5b27a137378 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed408b632dc69d42cfd0445ffc4519e0 |
publicationDate |
2017-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
HU-E031647-T2 |
titleOfInvention |
Antibodies and Methods of Use for Factor XA Inhibitors |
abstract |
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. |
priorityDate |
2007-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |